Journal article

Delivering affordable cancer care in high-income countries

Richard Sullivan, Jeffrey Peppercorn, Karol Sikora, John Zalcberg, Neal J Meropol, Eitan Amir, David Khayat, Peter Boyle, Philippe Autier, Ian F Tannock, Tito Fojo, Jim Siderov, Steve Williamson, Silvia Camporesi, J Gordon McVie, Arnie D Purushotham, Peter Naredi, Alexander Eggermont, Murray F Brennan, Michael L Steinberg Show all

The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2011

Grants

Funding Acknowledgements

RS has received research funding from Pfizer and Novartis, and has received payment for lectures by Celgene. MA has received consultancy and honoraria fees from Amgen, Sandoz, Helsinn, Johnson & Johnson, Norvartis, Roche, Merck, Pierre Fabre, Hospira and Pfizer, and honoraria from Baxter. JP has received consultancy fees from Aveo Pharmaceuticals, Bayer, Celgene, Genentech, Novartis, and Heathwell Foundation. He has received honoraria from Genentech, and Novartis and research support from Novartis. JZ has acted as a consultant for Amgen, ARIAD, Novartis, Pfizer, Roche, Sanofi-Aventis, Abraxis, Abbott, Patrys, MSD, Imclone, Bayer, and Abbott and has received research funding from Amgen, MerckSerono, Novartis, Pfizer, Roche, and Sanofi. NB is employed by Susan G Komen for the Cure. NJM has received consultancy fees from AstraZeneca, Genomic Health, Saladax, Sanofi-Aventis, Helsinn, Pfizer, Veridex, Genentech, and Amgen and honoraria from Biogen. KAS has received research support from Actelion Pharmaceuticals, Allergan, Alnylam Pharmaceuticals, Amgen, Amylin Pharmaceuticals, Astellas Pharma, Bristol-Myers Squibb, Inspire Pharmaceuticals, Johnson & Johnson, Kureha Corporation, Medtronic, Merck & Co, Nabi Biopharmaceuticals, NovaCardia, Novartis, OSI Eyetech, Sanofi-Aventis US, Scios, Tengion, Theravance, Thomson Healthcare, and Vertex Pharmaceuticals. He has received consulting fees from Advanced Health Media, the Certified Medical Representatives Institute, the Commonwealth Fund, EnablEd, Forest Laboratories, GlaxoSmithKline, Johnson & Johnson, LifeMasters Supported SelfCare, McKinsey & Company, Medical Decisions Network Medtronic, Merck & Co, National Pharmaceutical Council, Novartis, Novo Nordisk, Orexigen Therapeutics, Quintiles Transnational Corp, Social and Scientific Systems, Wallen and Associates, and WebMD. He holds equity in Alnylam Pharmaceuticals, Cancer Consultants Inc, Faculty Connection, General Electric Company, the Manufacturers Life Insurance Company, PepsiCo Inc, the Physician Education Leadership Institute, Procter & Gamble, and Tellus. PC is employed by the ABPI, which is a trade association for the UK pharmaceutical industry, and until March, 2010, was employed by Roche UK. DT has received research funding from a range of public and private bodies, including NICE, the Department of Health, Alliance Boots, Pfizer, and the Pharmaceutical Research and Manufacturers of America. JG has received consultancy fees from Bristol-Myers Squibb, Novartis and Pfizer. SW has received honoraria from Amgen, ISIS Pharma, and payment for educational presentation from Roche. DKh has received consultancy fees from Roche, AstraZeneca, and Sanofi-Aventis. All other authors declared that they have no conflicts of interest.JP is supported by the Conquer Cancer Foundation and the Greenwall Foundation for Bioethics. Research for Part 5 was funded by the Chair's Fund, UCLA Department of Radiation Oncology and by the Herculesstichting and Fonds Wetenschappelijk Onderzoek-Vlaanderen. PJE received funding from the UK Department of Health NIHR Biomedical Research Centre's funding scheme. JG and NGB thank Diana Rowden, Matthew Moore, Chandini Portteus, and Elizabeth Thompson from Susan G Komen for the Cure for support in the preparation of Part 9. ADP is supported by Department of Health via the National Institute for Health Research (NIHR) Comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust.